These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
729 related articles for article (PubMed ID: 31239321)
1. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321 [TBL] [Abstract][Full Text] [Related]
2. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413 [TBL] [Abstract][Full Text] [Related]
3. Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. Saba NF; Blumenschein G; Guigay J; Licitra L; Fayette J; Harrington KJ; Kiyota N; Gillison ML; Ferris RL; Jayaprakash V; Li L; Brossart P Oral Oncol; 2019 Sep; 96():7-14. PubMed ID: 31422216 [TBL] [Abstract][Full Text] [Related]
4. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929 [TBL] [Abstract][Full Text] [Related]
5. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. Haddad RI; Harrington K; Tahara M; Ferris RL; Gillison M; Fayette J; Daste A; Koralewski P; Zurawski B; Taberna M; Saba NF; Mak M; Kawecki A; Girotto G; Alvarez Avitia MA; Even C; Toledo JGR; Guminski A; Müller-Richter U; Kiyota N; Roberts M; Khan TA; Miller-Moslin K; Wei L; Argiris A J Clin Oncol; 2023 Apr; 41(12):2166-2180. PubMed ID: 36473143 [TBL] [Abstract][Full Text] [Related]
6. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. Kiyota N; Hasegawa Y; Takahashi S; Yokota T; Yen CJ; Iwae S; Shimizu Y; Hong RL; Goto M; Kang JH; Sum Kenneth Li W; Ferris RL; Gillison M; Namba Y; Monga M; Lynch M; Tahara M Oral Oncol; 2017 Oct; 73():138-146. PubMed ID: 28939066 [TBL] [Abstract][Full Text] [Related]
7. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma. Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940 [TBL] [Abstract][Full Text] [Related]
8. A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck. Cocks K; Contente M; Simpson S; DeRosa M; Taylor FC; Shaw JW Pharmacoeconomics; 2019 Aug; 37(8):1041-1047. PubMed ID: 30972702 [TBL] [Abstract][Full Text] [Related]
9. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283 [TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck. Saada-Bouzid E; Peyrade F; Guigay J Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146 [TBL] [Abstract][Full Text] [Related]
12. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Gillison ML; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Li L; Ferris RL Oncologist; 2018 Sep; 23(9):1079-1082. PubMed ID: 29866947 [TBL] [Abstract][Full Text] [Related]
13. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. Gillison ML; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Jayaprakash V; Wei L; Ferris RL Oncologist; 2022 Mar; 27(2):e194-e198. PubMed ID: 35641218 [TBL] [Abstract][Full Text] [Related]
14. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970 [TBL] [Abstract][Full Text] [Related]
15. Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study. Forster MD; Dillon MT; Kocsis J; Remenár É; Pajkos G; Rolland F; Greenberg J; Harrington KJ Eur J Cancer; 2019 Dec; 123():36-47. PubMed ID: 31648099 [TBL] [Abstract][Full Text] [Related]
16. Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141). Yen CJ; Kiyota N; Hanai N; Takahashi S; Yokota T; Iwae S; Shimizu Y; Hong RL; Goto M; Kang JH; Li WSK; Ferris RL; Gillison M; Endo T; Jayaprakash V; Tahara M Head Neck; 2020 Oct; 42(10):2852-2862. PubMed ID: 32583557 [TBL] [Abstract][Full Text] [Related]
17. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Seiwert TY; Kochanny S; Wood K; Worden FP; Adkins D; Wade JL; Sleckman BG; Anderson D; Brisson RJ; Karrison T; Stadler WM; Vokes EE Cancer; 2020 Jul; 126(14):3237-3243. PubMed ID: 32365226 [TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma. Zargar M; McFarlane T; Chan KKW; Wong WWL Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380 [TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ; Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740 [TBL] [Abstract][Full Text] [Related]
20. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial. Guo Y; Luo Y; Zhang Q; Huang X; Li Z; Shen L; Feng J; Sun Y; Yang K; Ge M; Zhu X; Wang L; Liu Y; He X; Bai C; Xue K; Zeng Y; Chang X; Chen W; Lin T Eur J Cancer; 2021 Oct; 156():35-45. PubMed ID: 34418665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]